StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “hold” rating on the stock.
Brooklyn ImmunoTherapeutics Trading Up 7.9 %
BTX stock opened at $1.09 on Friday. The business’s 50-day moving average is $1.48 and its 200 day moving average is $1.81. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The stock has a market cap of $64.12 million, a price-to-earnings ratio of -0.48 and a beta of 4.61.
About Brooklyn ImmunoTherapeutics
Recommended Stories
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Upcoming IPO Stock Lockup Period, Explained
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.